Y-mAbs Therapeutics
YMAB

$12.53

1.62%

Market Cap: 550M

About: Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Employees: 100

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 6 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

171% more capital invested

Capital invested by funds: $138M [Q4 2023] → $374M (+$236M) [Q1 2024]

6.17% more ownership

Funds ownership: 46.38% [Q4 2023] → 52.55% (+6.17%) [Q1 2024]

0% more funds holding

Funds holding: 94 [Q4 2023] → 94 (+0) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 18

7% less call options, than puts

Call options by funds: $748K | Put options by funds: $808K

43% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 44

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$21

68%

upside

Avg. target

$23

85%

upside

High target

$26

108%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Jones Trading Justin Walsh	84%upside $23	Buy Initiated	11 Jul 2024
Truist Securities Nicole Germino	68%upside $21	Buy Initiated	28 Jun 2024
HC Wainwright & Co. Robert Burns	76%upside $22	Buy Maintained	13 May 2024
Canaccord Genuity Bill Maughan	108%upside $26	Buy Maintained	4 Mar 2024
BMO Capital Etzer Darout	108%upside $26	Outperform Maintained	4 Mar 2024

See Analyst Rankings

Financial journalist opinion

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB

NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of stock of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB):

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer.

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

Y-MABS SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of the Company's Long-Term Shareholders and Encourages Investors to Contact the Firm

PHILADELPHIA, PA / ACCESSWIRE / June 14, 2024 / Kaskela Law LLC announces that it is investigating Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) ("Y-mAbs") on behalf of the company's long-term shareholders. Recently an amended securities fraud complaint was filed against Y-mAbs on behalf of certain investors who purchased shares of the company's stock between October 6, 2020, and October 28, 2022.

Y-MABS SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of the Company's Long-Term Shareholders and Encourages Investors to Contact the Firm

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that preclinical GD2-SADA data will be presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting taking place June 8 – 11, 2024, in Toronto, Canada.

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer.

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 through June 4, 2024, in Chicago, IL.

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new interim data from the Phase 2 Trial 201 of naxitamab in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”) in patients with relapsed or refractory high-risk neuroblastoma with residual disease limited to bone and/or bone marrow. The results are summarized in poster presentations scheduled to be presented today, June 1, 2024, at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, IL.

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2024 Earnings Call Transcript

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Courtney Dugan - Head-Investor Relations Michael Rossi - President and Chief Executive Officer Bo Kruse - Chief Financial Officer Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Bill Maughan - Canaccord Genuity Nick Unan - BMO Capital Markets David Nierengarten - Wedbush Securities Operator Good morning, and welcome to Y-mAbs Therapeutics Inc. Earnings Conference Call for the First Quarter of 2024. At this time, all participants are in a listen-only mode.

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2024 Earnings Call Transcript

Zacks Investment Research

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.15 per share a year ago.

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

See News Rankings